Overview

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

Status:
Completed
Trial end date:
2016-11-03
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir (SOF)+ ribavirin (RBV), with or without Pegylated interferon alfa (Peg-IFNα-2a/ PEG)) in participants with chronic genotype (GT)-1, 2, 3, and 6 Hepatitis C virus (HCV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ribavirin
Sofosbuvir